More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

Ethics Board Approval Granted for Lexaria Receives Ethics Board Approval for 12-Week Phase 1b DehydraTECH GLP-1 Study in ...

The Company is also announcing that clinical test article manufacturing for all planned Study arms has already been completed. This includes production for the four planned DehydraTECH formulation ...

Glucagon-like peptide-1 (GLP-1) agonist are a family of medications that help manage blood sugar in patients with type 2 ...

Here’s what to know about Rybelsus semaglutide tablets versus injections for weight loss and diabetes. This medication doesn’t have FDA approval for weight loss, but some healthcare providers ...

DehydraTECH clinical test article manufacturing has been completed KELOWNA, BC / ACCESSWIRE / November 13, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global i ...

The study showed that Rybelsus, the company's oral form of semaglutide, slashed the risk of major cardiovascular events by 14% in type 2 diabetes patients who also face cardiovascular or kidney ...

Bernstein said Novo Nordisk’s (NVO) recently released SOUL study results for Rybelsus in the reduction of major cardiovascular events in diabetic patients were modest and not as robust as ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...